Q-omics provides the consensus-scored ZNF354B profile across patient tissues and cancer cell-line models. ZNF354B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, ZNF354B is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, ZNF354B RNA expression shows 20,421 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KICH, KIRC, and THYM as cancer lineages where ZNF354B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF354B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF354B survival associations across molecular data types. ZNF354B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF354B RNA expression–survival associations across cancer types. High ZNF354B expression shows unfavorable associations in KICH, UVM, LGG and LIHC, but favorable associations in READ and UCS. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KICH as the clearest survival context for ZNF354B RNA expression.
This table summarizes ZNF354B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF354B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF354B shows lower tumor expression in THCA and higher tumor expression in KIRC, LIHC, COAD, BLCA and HNSC. The KIRC box plot shows higher ZNF354B RNA expression in tumor versus normal tissue (log2 FC = +0.802, t-test p < 0.001).
This table shows molecular features associated with ZNF354B in patient tissues and cancer cell lines. In patient samples, ZNF354B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF354B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
